Estimate The Effect Of Repeat-Dose Rifampin On The Pharmacokinetics Of CP-690,550 In Healthy Volunteers

Phase 1

Completed

• Conditions: Healthy
• Interventions: Drug: Tasocitinib (CP-690,550) plus Rifampin

• Registration Number: NCT01204112
• Lead Sponsor: Pfizer

Brief Summary

The current study is designed to estimate the effect of rifampin (600 mg orally every 24 hours for 7 days) on pharmacokinetics of single 30 mg dose (CP-690,550) in normal healthy volunteers

Detailed Description

Not available

Study Timeline

• Study Start: 2010-09
• Study First Submitted: 2010-09-15
• Study First Submitted QC: 2010-09-15
• Study First Posted: 2010-09-17
• Status Verified: 2010-10
• Primary Completion: 2010-10
• Study Completion: 2010-10
• Last Update Submitted: 2010-10-21
• Last Update Posted: 2010-10-22

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 12

Inclusion Criteria

• Healthy male and/or female subjects (of non-childbearing potential)

Exclusion Criteria

• Clinically significant disease or condition
• Recent serious infection

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: SINGLE_GROUP

Arm && Interventions

Group	Intervention	Description
Tasocitinib (CP-690,550) plus Rifampin	Tasocitinib (CP-690,550) plus Rifampin	-

Primary Outcome Measures

Name	Time	Method
AUCinf of tasocitinib (CP-690,550)	9 days
Cmax of tasocitinib (CP-690,550)	9 days

Secondary Outcome Measures

Name	Time	Method
AUClast, Tmax, t1/2 of tasocitinib (CP-690,550)	9 days
Safety: clinical laboratory abnormalities, AE reporting, and vital signs (blood pressure/pulse rate).	9 days

Trial Locations

Locations (1)

Pfizer Investigational Site; 🇺🇸 New Haven, Connecticut, United States